HF
TXG icon

HRT Financial’s 10x Genomics TXG Stock Holding History

HRT Financial’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-80,927
Closed -$1.72M – 5374
2026
Q1 		$1.72M Sell
80,927
-100,225
-55% -$2M ﹤0.01% 1718
2025
Q4 		$2.95M Buy
+181,152
New +$2.74M 0.01% 1052
2024
Q4 		– Sell
-38,721
Closed -$874K – 3272
2024
Q3 		$874K Buy
+38,721
New +$801K ﹤0.01% 1308
2024
Q1 		– Sell
-40,050
Closed -$2.24M – 3114
2023
Q4 		$2.24M Buy
+40,050
New +$1.74M 0.02% 602
2023
Q3 		– Sell
-38,178
Closed -$2.13M – 3119
2023
Q2 		$2.13M Sell
38,178
-39,723
-51% -$2.15M 0.02% 587
2023
Q1 		$4.35M Buy
77,901
+71,590
+1,134% +$3.34M 0.05% 287
2022
Q4 		$229K Buy
+6,311
New +$206K ﹤0.01% 1885

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HRT Financial's TXG Position: Q2 2026 in Review

HRT Financial sold out of 10x Genomics (TXG) in Q2 2026, closing a stake of 80,927 shares — an estimated $1.72M sold.

HRT Financial first reported a position in TXG in Q4 2022 and held it in 7 quarters. The position peaked at $4.35M in Q1 2023. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • HRT Financial reported no remaining 10x Genomics position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 80,927 10x Genomics shares in Q2 2026, an estimated $1.72M.
  • HRT Financial first reported a position in 10x Genomics in Q4 2022 and held it in 7 quarters.
  • HRT Financial's 10x Genomics position peaked at $4.35M in Q1 2023.
  • 392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.